person · Reporting owner

Field Katharyn

Disclosed activity across 6 companies

Tapewire entity: 24682
SEC CIK: 0002029888

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Advasa Holdings, Inc.ADBT · Entity 9245	Chief Financial Officer	August 11, 2026	August 11, 2026
BioRestorative Therapies, Inc.BRTX · Entity 8277	Director	June 10, 2026	June 17, 2026
LOGPROSTYLE INC.LGPS · Entity 7527	Director · Director and Executive Officer	March 18, 2026	March 18, 2026
Nuwellis, Inc.NUWE · Entity 8478	Director	January 21, 2026	February 11, 2026
Virpax Pharmaceuticals, Inc.VRPX · Entity 84306	Director	July 05, 2024	July 10, 2024
iSpecimen Inc.ISPC · Entity 8372	Director	September 25, 2024	September 27, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Advasa Holdings, Inc.

Report date August 11, 2026 · Filed August 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.00001SEC Table I · non-derivative	Direct	0	Reported balance Holding disclosure · report date 2026-08-11 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 0

BioRestorative Therapies, Inc.

Report date June 10, 2026 · Filed June 17, 2026

This filing explicitly reported no securities owned.

LOGPROSTYLE INC.

Report date March 18, 2026 · Filed March 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Shares, no par valueSEC Table I · non-derivative	Direct	0	Reported balance Holding disclosure · report date 2026-03-18 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 0

Nuwellis, Inc.

Report date January 21, 2026 · Filed February 11, 2026

This filing explicitly reported no securities owned.

Virpax Pharmaceuticals, Inc.

Report date July 05, 2024 · Filed July 10, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2034-07-04	Direct	2,500	Reported balance After 2024-07-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-07-05 · Grant · Acquired 2,500 · Balance 2,500 F1: The option vests in full on the twelve-month anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in full on the twelve-month anniversary of the grant date.

iSpecimen Inc.

Report date September 25, 2024 · Filed September 27, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.12 · Expires 2034-09-24	Direct	168	Reported balance After 2024-09-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-09-25 · Grant · Acquired 168 · Balance 168 F1: Represents stock options granted to the reporting person on September 25, 2024, pursuant to the Issuer's Amended and Restated Stock Incentive Plan, and reflects the Issuer's 20-for-1 reverse stock split effective as of 4:30 p.m., Eastern Time, on September 13, 2024. The stock options vest in respect to 84 shares on each of September 30, 2024 and December 31, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Represents stock options granted to the reporting person on September 25, 2024, pursuant to the Issuer's Amended and Restated Stock Incentive Plan, and reflects the Issuer's 20-for-1 reverse stock split effective as of 4:30 p.m., Eastern Time, on September 13, 2024. The stock options vest in respect to 84 shares on each of September 30, 2024 and December 31, 2024.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 25, 2024 Filed Sep 27, 2024 23:19 UTC	iSpecimen Inc. ISPC · Entity 8372	GrantOption · Derivative	168	$5.12 Strike: $5.12	$860.16	Disclosure SEC source: 0001104659-24-103805 · tm2425111-5_4seq1.xml · derivative · entry 1 Field Katharyn · CIK 0002029888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168 Underlying: Common Stock · 168 shares Expires 2034-09-24 F1 · derivative.exercise_date: Represents stock options granted to the reporting person on September 25, 2024, pursuant to the Issuer's Amended and Restated Stock Incentive Plan, and reflects the Issuer's 20-for-1 reverse stock split effective as of 4:30 p.m., Eastern Time, on September 13, 2024. The stock options vest in respect to 84 shares on each of September 30, 2024 and December 31, 2024. Read SEC document
July 05, 2024 Filed Jul 10, 2024 20:10 UTC	Virpax Pharmaceuticals, Inc. VRPX · Entity 84306	GrantStock Option (right to buy) · Derivative	2,500	$0.00 Strike: $0.58	$0.00	Disclosure SEC source: 0001213900-24-060500 · ownership.xml · derivative · entry 1 Field Katharyn · CIK 0002029888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2034-07-04 F1 · derivative.exercise_date: The option vests in full on the twelve-month anniversary of the grant date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.